Jefferies Starts Neuroderm Ltd (NDRM) at Buy, $17 PT

Jefferies initiates coverage on Neuroderm Ltd (NASDAQ: NDRM) with a Buy rating and a price target of $17.00.

Analyst Thomas Wei said, "We view NDRM's Parkinson’s disease (PD) assets, ND0612L and ND0612H, as two relatively de-risked drugs among mid-stage biotech companies. As an actual liquid formulation of levodopa/carbidopa, 0612L and H should provide substantial benefit to later-stage PD patients from continuous dosing that current oral formulations lack."

For an analyst ratings summary and ratings history on Neuroderm Ltd click here. For more ratings news on Neuroderm Ltd click here.

Shares of Neuroderm Ltd closed at $8.04 yesterday.

You May Also Be Interested In

• Wedbush Starts Aktis Oncology (AKTS) at Outperform
• Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $55 at Guggenheim
• Home Depot (HD) PT Raised to $354 at Bernstein SocGen Group